Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CADL Candel Therapeutics	$4.85 -4.2%	$5.22	$3.79 ▼ $14.60	$242.99M	-0.87	1.47 million shs	803,385 shs
ESPR Esperion Therapeutics	$1.00 +1.6%	$0.97	$0.69 ▼ $3.94	$198.20M	0.67	4.89 million shs	2.89 million shs
LXEO Lexeo Therapeutics	$4.22 +5.0%	$3.54	$1.45 ▼ $19.50	$140.09M	0.52	537,575 shs	663,299 shs
SLRN Acelyrin	$2.27	$2.30	$1.85 ▼ $7.25	$229.17M	1.07	1.27 million shs	N/A

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CADL Candel Therapeutics	+3.27%	+8.35%	-8.50%	-9.16%	-18.39%
ESPR Esperion Therapeutics	-0.93%	-5.35%	+15.22%	-30.18%	-55.66%
LXEO Lexeo Therapeutics	-2.43%	+1.52%	+45.65%	+28.43%	-74.94%
SLRN Acelyrin	0.00%	0.00%	0.00%	-9.56%	-48.53%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CADL Candel Therapeutics	1.97 of 5 stars	3.5	1.0	0.0	0.0	2.6	0.8	0.6
ESPR Esperion Therapeutics	4.1491 of 5 stars	3.4	3.0	0.0	3.9	2.2	1.7	0.6
LXEO Lexeo Therapeutics	2.1612 of 5 stars	3.5	1.0	0.0	0.0	1.6	2.5	0.6
SLRN Acelyrin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CADL Candel Therapeutics	3.00	Buy	$22.00	353.61% Upside
ESPR Esperion Therapeutics	2.80	Moderate Buy	$7.00	600.00% Upside
LXEO Lexeo Therapeutics	3.00	Buy	$16.60	293.36% Upside
SLRN Acelyrin	2.40	Hold	$9.60	322.91% Upside

Current Analyst Ratings Breakdown

Latest LXEO, ESPR, SLRN, and CADL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/30/2025	CADL Candel Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$23.00
6/17/2025	ESPR Esperion Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
5/30/2025	LXEO Lexeo Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$16.00 ➝ $10.00
5/16/2025	LXEO Lexeo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$23.00 ➝ $15.00
5/13/2025	LXEO Lexeo Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$22.00 ➝ $20.00
5/7/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $4.00
4/25/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/25/2025	ESPR Esperion Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
4/17/2025	ESPR Esperion Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$4.00 ➝ $3.00
4/11/2025	CADL Candel Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$19.00 ➝ $19.00
4/8/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00

(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CADL Candel Therapeutics	$120K	2,024.88	N/A	N/A	$1.41 per share	3.44
ESPR Esperion Therapeutics	$332.31M	0.60	$0.02 per share	41.35	($1.97) per share	-0.51
LXEO Lexeo Therapeutics	N/A	N/A	N/A	N/A	$3.53 per share	N/A
SLRN Acelyrin	N/A	N/A	N/A	N/A	$6.74 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CADL Candel Therapeutics	-$55.18M	-$1.34	N/A	N/A	N/A	N/A	-136.74%	-63.13%	8/12/2025 (Estimated)
ESPR Esperion Therapeutics	-$51.74M	-$0.80	N/A	N/A	N/A	-59.03%	-0.91%	-29.47%	8/11/2025 (Estimated)
LXEO Lexeo Therapeutics	-$98.33M	-$3.30	N/A	N/A	N/A	N/A	-85.86%	-68.48%	8/11/2025 (Estimated)
SLRN Acelyrin	-$381.64M	-$2.69	N/A	N/A	N/A	N/A	-44.12%	-39.02%	8/12/2025 (Estimated)

Latest LXEO, ESPR, SLRN, and CADL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	SLRN Acelyrin	-$0.95	-$0.55	+$0.40	-$0.55	N/A	N/A
5/13/2025	Q1 2025	CADL Candel Therapeutics	-$0.24	$0.13	+$0.37	$0.13	N/A	N/A
5/12/2025	Q1 2025	LXEO Lexeo Therapeutics	-$0.80	-$0.99	-$0.19	-$0.99	N/A	N/A
5/6/2025	Q1 2025	ESPR Esperion Therapeutics	-$0.18	-$0.21	-$0.03	-$0.21	$54.97 million	$65.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	N/A
ESPR Esperion Therapeutics	N/A	N/A	N/A	N/A	N/A
LXEO Lexeo Therapeutics	N/A	N/A	N/A	N/A	N/A
SLRN Acelyrin	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CADL Candel Therapeutics	0.01	4.64	4.64
ESPR Esperion Therapeutics	N/A	1.18	0.81
LXEO Lexeo Therapeutics	0.01	3.42	3.42
SLRN Acelyrin	N/A	7.15	7.15

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CADL Candel Therapeutics	13.93%
ESPR Esperion Therapeutics	47.39%
LXEO Lexeo Therapeutics	60.67%
SLRN Acelyrin	87.31%

Insider Ownership

Company	Insider Ownership
CADL Candel Therapeutics	16.60%
ESPR Esperion Therapeutics	1.70%
LXEO Lexeo Therapeutics	5.30%
SLRN Acelyrin	13.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CADL Candel Therapeutics	60	50.10 million	41.79 million	Optionable
ESPR Esperion Therapeutics	200	198.20 million	194.83 million	Optionable
LXEO Lexeo Therapeutics	58	33.20 million	31.44 million	Not Optionable
SLRN Acelyrin	135	100.95 million	86.68 million	Optionable

LXEO, ESPR, SLRN, and CADL Headlines

Recent News About These Companies

ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

May 13, 2025 | globenewswire.com

Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis

May 6, 2025 | globenewswire.com

Acelyrin urges stockholders to vote for proposed merger with Alumis

May 2, 2025 | finance.yahoo.com

ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis

May 1, 2025 | globenewswire.com

Alumis and ACELYRIN Announce Amended Merger Agreement

April 21, 2025 | globenewswire.com

ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN

April 16, 2025 | businesswire.com

Alumis Inc.; ACELYRIN, INC.: Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger

April 5, 2025 | finanznachrichten.de

Alumis Inc. and ACELYRIN, INC. File Joint Definitive Proxy Statement for Proposed Merger

April 5, 2025 | finanznachrichten.de

STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating The Merger - SLRN, TURN, BHLB, MHLD

March 30, 2025 | morningstar.comM

Insider Selling: Acelyrin, Inc. (NASDAQ:SLRN) Insider Sells 3,913 Shares of Stock

March 20, 2025 | insidertrades.com

Acelyrin, Inc. (SLRN): One of the Best Short-Term Stocks to Buy Right Now

March 18, 2025 | msn.com

ACELYRIN Adopts Limited-Duration Stockholder Rights Plan

March 13, 2025 | globenewswire.com

Acelyrin: Potential Buyout Led By Concentra Biosciences

March 12, 2025 | seekingalpha.com

Is Acelyrin, Inc. (SLRN) the Best Micro Cap Stock to Buy Now?

March 7, 2025 | insidermonkey.com

ACELYRIN, INC.: ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger

March 4, 2025 | finanznachrichten.de

Acelyrin says Concentra indication not expected to result in superior proposal

March 4, 2025 | markets.businessinsider.com

Acelyrin falls as Acelyrin reaffirms deal commitment

March 4, 2025 | msn.com

Acelyrin, Alumis reaffirm strategic, financial rationale of proposed merger

March 4, 2025 | markets.businessinsider.com

ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger

March 4, 2025 | globenewswire.com

ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger

March 4, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LXEO, ESPR, SLRN, and CADL Company Descriptions

Candel Therapeutics NASDAQ:CADL

$4.85 -0.21 (-4.15%)

Closing price 04:00 PM Eastern

Extended Trading

$4.88 +0.04 (+0.72%)

As of 06:12 PM Eastern

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Esperion Therapeutics NASDAQ:ESPR

$1.00 +0.02 (+1.58%)

Closing price 04:00 PM Eastern

Extended Trading

$1.01 +0.01 (+1.00%)

As of 06:26 PM Eastern

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Lexeo Therapeutics NASDAQ:LXEO

$4.22 +0.20 (+4.98%)

Closing price 04:00 PM Eastern

Extended Trading

$4.27 +0.05 (+1.18%)

As of 06:07 PM Eastern

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

Acelyrin NASDAQ:SLRN

$2.27 0.00 (0.00%)

As of 05/21/2025

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time